Skip to main content
Top
Published in: The Journal of Headache and Pain 4/2008

Open Access 01-08-2008 | Review

Meeting patient expectations in migraine treatment: what are the key endpoints?

Authors: Fabio Antonaci, Grazia Sances, Elena Guaschino, Ilaria De Cillis, Giorgio Bono, Giuseppe Nappi

Published in: The Journal of Headache and Pain | Issue 4/2008

Login to get access

Abstract

Clinical outcomes of migraine treatment are generally based on two major endpoints: acute pain resolution and effects on quality of life (QOL). Resolution of acute pain can be evaluated in a number of ways, each increasingly challenging to achieve; pain relief, pain freedom at 2 h, sustained pain-freedom, and SPF plus no adverse events (SNAE, the most challenging). QOL questionnaires help assess the burden of migraine and identify optimal treatments. Pain resolution and improved QOL form the basis of the ultimate target—meeting patient expectations, to achieve patient satisfaction. To achieve this, it is crucial to choose appropriate endpoints that reflect realistic treatment goals for individual patients. Moreover, SNAE can help discriminate between triptans, with almotriptan having the highest SNAE score. Kaplan–Meier plots are also relevant when evaluating migraine treatments. The use of symptomatic medication may lead to the paradoxical development of medication-overuse headache. In general practice, patients should use simple tools for pain measurement (e.g. headache diary) and a QOL questionnaire. A composite endpoint of pain resolution and QOL restoration would constitute a step forward in migraine management.
Literature
1.
go back to reference Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24 Suppl 1:1–160 Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24 Suppl 1:1–160
2.
go back to reference Lipton RB, Stewart WF, Von KM (1997) Burden of migraine: societal costs and therapeutic opportunities. Neurology 48:S4–S9 9071263, 1:STN:280:ByiB38vovFQ%3DCrossRefPubMed Lipton RB, Stewart WF, Von KM (1997) Burden of migraine: societal costs and therapeutic opportunities. Neurology 48:S4–S9 9071263, 1:STN:280:ByiB38vovFQ%3DCrossRefPubMed
3.
go back to reference Lipton RB, Stewart WF, Diamond S et al (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657 11554952, 10.1046/j.1526-4610.2001.041007646.x, 1:STN:280:DC%2BD3MrhtVKjtg%3D%3DCrossRefPubMed Lipton RB, Stewart WF, Diamond S et al (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646–657 11554952, 10.1046/j.1526-4610.2001.041007646.x, 1:STN:280:DC%2BD3MrhtVKjtg%3D%3DCrossRefPubMed
4.
go back to reference Mannix LK (2001) Epidemiology and impact of primary headache disorders. Med Clin North Am 85:887–895 11480263, 10.1016/S0025-7125(05)70349-7, 1:STN:280:DC%2BD3MvjtlWqtw%3D%3DCrossRefPubMed Mannix LK (2001) Epidemiology and impact of primary headache disorders. Med Clin North Am 85:887–895 11480263, 10.1016/S0025-7125(05)70349-7, 1:STN:280:DC%2BD3MvjtlWqtw%3D%3DCrossRefPubMed
5.
go back to reference Von KM, Stewart WF, Simon DJ et al (1998) Migraine and reduced work performance: a population-based diary study. Neurology 50:1741–1745CrossRef Von KM, Stewart WF, Simon DJ et al (1998) Migraine and reduced work performance: a population-based diary study. Neurology 50:1741–1745CrossRef
6.
go back to reference Hu XH, Markson LE, Lipton RB et al (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159:813–818 10219926, 10.1001/archinte.159.8.813, 1:STN:280:DyaK1M3jsFegsA%3D%3DCrossRefPubMed Hu XH, Markson LE, Lipton RB et al (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159:813–818 10219926, 10.1001/archinte.159.8.813, 1:STN:280:DyaK1M3jsFegsA%3D%3DCrossRefPubMed
7.
go back to reference Lipton RB, Diamond S, Reed M et al (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41:638–645 11554951, 10.1046/j.1526-4610.2001.041007638.x, 1:STN:280:DC%2BD3MrhtVKjsQ%3D%3DCrossRefPubMed Lipton RB, Diamond S, Reed M et al (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41:638–645 11554951, 10.1046/j.1526-4610.2001.041007638.x, 1:STN:280:DC%2BD3MrhtVKjsQ%3D%3DCrossRefPubMed
8.
go back to reference Edmeads J (2005) Defining response in migraine: which endpoints are important? Eur Neurol 53 Suppl 1:22–28 15920334, 10.1159/000085038CrossRefPubMed Edmeads J (2005) Defining response in migraine: which endpoints are important? Eur Neurol 53 Suppl 1:22–28 15920334, 10.1159/000085038CrossRefPubMed
9.
go back to reference Dodick DW, Sandrini G, Williams P (2007) Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21(1):73–82 17190530, 10.2165/00023210-200721010-00006, 1:CAS:528:DC%2BD2sXislClur8%3DCrossRefPubMed Dodick DW, Sandrini G, Williams P (2007) Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs 21(1):73–82 17190530, 10.2165/00023210-200721010-00006, 1:CAS:528:DC%2BD2sXislClur8%3DCrossRefPubMed
10.
go back to reference Antonaci F, Chimento P, Diener HC et al (2007) Lessons from placebo effects in migraine treatment. J Headache Pain 8:63–66 17361384, 10.1007/s10194-007-0360-4PubMedCentralCrossRefPubMed Antonaci F, Chimento P, Diener HC et al (2007) Lessons from placebo effects in migraine treatment. J Headache Pain 8:63–66 17361384, 10.1007/s10194-007-0360-4PubMedCentralCrossRefPubMed
11.
go back to reference Foley KA, Cady R, Martin V et al (2005) Treating early versus treating mild: timing of migraine prescription medicatons among patients with diagnosed migraine. Headache 45(5):538–4511 15953272, 10.1111/j.1526-4610.2005.05107.xCrossRefPubMed Foley KA, Cady R, Martin V et al (2005) Treating early versus treating mild: timing of migraine prescription medicatons among patients with diagnosed migraine. Headache 45(5):538–4511 15953272, 10.1111/j.1526-4610.2005.05107.xCrossRefPubMed
12.
go back to reference Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J (2008) Early vs. non-early intervention in acute migraine ‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia (in press) Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, Cunha L, Ivanoff N, Falques M, Fortea J (2008) Early vs. non-early intervention in acute migraine ‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia (in press)
13.
go back to reference Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans—serotonin 5-HT(1B/1D) agonists—in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675 11728541, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3DCrossRefPubMed Ferrari MD, Roon KI, Lipton RB et al (2001) Oral triptans—serotonin 5-HT(1B/1D) agonists—in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675 11728541, 10.1016/S0140-6736(01)06711-3, 1:CAS:528:DC%2BD3MXos1ajsro%3DCrossRefPubMed
14.
go back to reference Pascual J (2008) Almotriptan in triptan-naïve patients: new evidence of benefits, Cephalalgia (in press) Pascual J (2008) Almotriptan in triptan-naïve patients: new evidence of benefits, Cephalalgia (in press)
15.
go back to reference Dodick Diener HC, DW Goadsby PJ et al (2008) Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 28(1):35–40 17941878, 10.1111/j.1468-2982.2008.01617.xPubMed Dodick Diener HC, DW Goadsby PJ et al (2008) Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 28(1):35–40 17941878, 10.1111/j.1468-2982.2008.01617.xPubMed
16.
go back to reference Stewart WF, Lipton RB, Dowson AJ et al. (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56 (6 Suppl 1):S20–S28 11294956, 1:STN:280:DC%2BD3M3ivVGntA%3D%3DCrossRefPubMed Stewart WF, Lipton RB, Dowson AJ et al. (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56 (6 Suppl 1):S20–S28 11294956, 1:STN:280:DC%2BD3M3ivVGntA%3D%3DCrossRefPubMed
17.
go back to reference Brna P, Gordon K, Dooley J et al (2007) Health-related quality of life among Canadians with migraine. J Headache Pain 8(1):43–48 17361382, 10.1007/s10194-007-0320-4PubMedCentralCrossRefPubMed Brna P, Gordon K, Dooley J et al (2007) Health-related quality of life among Canadians with migraine. J Headache Pain 8(1):43–48 17361382, 10.1007/s10194-007-0320-4PubMedCentralCrossRefPubMed
18.
go back to reference Rozen TD, Swanson JD, Stang PE et al (1999) Increasing incidence of medically recognized migraine headache in a United States population. Neurology 53:1468–1473 10534253, 1:STN:280:DC%2BD3c%2FgtFyhsg%3D%3DCrossRefPubMed Rozen TD, Swanson JD, Stang PE et al (1999) Increasing incidence of medically recognized migraine headache in a United States population. Neurology 53:1468–1473 10534253, 1:STN:280:DC%2BD3c%2FgtFyhsg%3D%3DCrossRefPubMed
19.
go back to reference Nappi G, Jensen R, Nappi RE et al (2006) Diaries and calendars for migraine: a review. Cephalalgia 26(8):905–916 16886925, 10.1111/j.1468-2982.2006.01155.x, 1:STN:280:DC%2BD28rgt12ltQ%3D%3DCrossRefPubMed Nappi G, Jensen R, Nappi RE et al (2006) Diaries and calendars for migraine: a review. Cephalalgia 26(8):905–916 16886925, 10.1111/j.1468-2982.2006.01155.x, 1:STN:280:DC%2BD28rgt12ltQ%3D%3DCrossRefPubMed
20.
go back to reference Hartmaier SL, Santanello NC, Epstein RS et al (1995) Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 35(6):320–329 7635717, 10.1111/j.1526-4610.1995.hed3506320.x, 1:STN:280:ByqA283lt1E%3DCrossRefPubMed Hartmaier SL, Santanello NC, Epstein RS et al (1995) Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 35(6):320–329 7635717, 10.1111/j.1526-4610.1995.hed3506320.x, 1:STN:280:ByqA283lt1E%3DCrossRefPubMed
21.
go back to reference Santanello NC, Hartmaier SL, Epstein RS et al (1995) Validation of a new quality of life questionnaire for acute migraine headache. Headache 35(6):330–337 7635718, 10.1111/j.1526-4610.1995.hed3506330.x, 1:STN:280:ByqA283lt1I%3DCrossRefPubMed Santanello NC, Hartmaier SL, Epstein RS et al (1995) Validation of a new quality of life questionnaire for acute migraine headache. Headache 35(6):330–337 7635718, 10.1111/j.1526-4610.1995.hed3506330.x, 1:STN:280:ByqA283lt1I%3DCrossRefPubMed
22.
go back to reference Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF36). Med Care 30:473–483 1593914, 10.1097/00005650-199206000-00002CrossRefPubMed Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF36). Med Care 30:473–483 1593914, 10.1097/00005650-199206000-00002CrossRefPubMed
23.
go back to reference Gladstone J, Eross E, Dodick D (2003) Chronic daily headache: a rational approach to a challenging problem. Semin Neurol 23(3):256–276 Gladstone J, Eross E, Dodick D (2003) Chronic daily headache: a rational approach to a challenging problem. Semin Neurol 23(3):256–276
24.
go back to reference Dowson AJ, Dodick DW, Limroth V (2005) Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs 19(6):483–497 15962999, 10.2165/00023210-200519060-00002CrossRefPubMed Dowson AJ, Dodick DW, Limroth V (2005) Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs 19(6):483–497 15962999, 10.2165/00023210-200519060-00002CrossRefPubMed
25.
go back to reference Saper JR (2005) Editorial to the guidelines for trials of behavioral treatments for recurrent headache. Headache 45(Suppl 2):S90–S91 15921505, 10.1111/j.1526-4610.2005.4502002.xCrossRefPubMed Saper JR (2005) Editorial to the guidelines for trials of behavioral treatments for recurrent headache. Headache 45(Suppl 2):S90–S91 15921505, 10.1111/j.1526-4610.2005.4502002.xCrossRefPubMed
Metadata
Title
Meeting patient expectations in migraine treatment: what are the key endpoints?
Authors
Fabio Antonaci
Grazia Sances
Elena Guaschino
Ilaria De Cillis
Giorgio Bono
Giuseppe Nappi
Publication date
01-08-2008
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 4/2008
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-008-0052-8

Other articles of this Issue 4/2008

The Journal of Headache and Pain 4/2008 Go to the issue